521 related articles for article (PubMed ID: 28869548)
1. Polymethoxyflavones: Novel β-Secretase (BACE1) Inhibitors from Citrus Peels.
Youn K; Yu Y; Lee J; Jeong WS; Ho CT; Jun M
Nutrients; 2017 Sep; 9(9):. PubMed ID: 28869548
[TBL] [Abstract][Full Text] [Related]
2. BACE1 molecular docking and anti-Alzheimer's disease activities of ginsenosides.
Choi RJ; Roy A; Jung HJ; Ali MY; Min BS; Park CH; Yokozawa T; Fan TP; Choi JS; Jung HA
J Ethnopharmacol; 2016 Aug; 190():219-30. PubMed ID: 27275774
[TBL] [Abstract][Full Text] [Related]
3. Flavonols and flavones as BACE-1 inhibitors: structure-activity relationship in cell-free, cell-based and in silico studies reveal novel pharmacophore features.
Shimmyo Y; Kihara T; Akaike A; Niidome T; Sugimoto H
Biochim Biophys Acta; 2008 May; 1780(5):819-25. PubMed ID: 18295609
[TBL] [Abstract][Full Text] [Related]
4. Screening and Elucidation of Selected Natural Compounds for Anti- Alzheimer's Potential Targeting BACE-1 Enzyme: A Case Computational Study.
Ahmad SS; Akhtar S; Danish Rizvi SM; Kamal MA; Sayeed U; Khan MKA; Siddiqui MH; Arif JM
Curr Comput Aided Drug Des; 2017 Nov; 13(4):311-318. PubMed ID: 28413992
[TBL] [Abstract][Full Text] [Related]
5. Inhibitory activities of major anthraquinones and other constituents from Cassia obtusifolia against β-secretase and cholinesterases.
Jung HA; Ali MY; Jung HJ; Jeong HO; Chung HY; Choi JS
J Ethnopharmacol; 2016 Sep; 191():152-160. PubMed ID: 27321278
[TBL] [Abstract][Full Text] [Related]
6. In Silico Docking and In Vitro Approaches towards BACE1 and Cholinesterases Inhibitory Effect of Citrus Flavanones.
Lee S; Youn K; Lim G; Lee J; Jun M
Molecules; 2018 Jun; 23(7):. PubMed ID: 29932100
[TBL] [Abstract][Full Text] [Related]
7. Molecular insights into the inhibitory mechanism of bi-functional bis-tryptoline triazole against β-secretase (BACE1) enzyme.
Narang SS; Goyal D; Goyal B
Amino Acids; 2019 Nov; 51(10-12):1593-1607. PubMed ID: 31654211
[TBL] [Abstract][Full Text] [Related]
8. Molecular docking based virtual screening of natural compounds as potential BACE1 inhibitors: 3D QSAR pharmacophore mapping and molecular dynamics analysis.
Kumar A; Roy S; Tripathi S; Sharma A
J Biomol Struct Dyn; 2016; 34(2):239-49. PubMed ID: 25707809
[TBL] [Abstract][Full Text] [Related]
9. Is BACE1 a suitable therapeutic target for the treatment of Alzheimer's disease? Current strategies and future directions.
Klaver DW; Wilce MC; Cui H; Hung AC; Gasperini R; Foa L; Small DH
Biol Chem; 2010 Aug; 391(8):849-59. PubMed ID: 20731541
[TBL] [Abstract][Full Text] [Related]
10. The Identification of Biochanin A as a Potent and Selective β-Site App-Cleaving Enzyme 1 (Bace1) Inhibitor.
Youn K; Park JH; Lee J; Jeong WS; Ho CT; Jun M
Nutrients; 2016 Oct; 8(10):. PubMed ID: 27754406
[TBL] [Abstract][Full Text] [Related]
11. BACE1 in Alzheimer's disease.
Sathya M; Premkumar P; Karthick C; Moorthi P; Jayachandran KS; Anusuyadevi M
Clin Chim Acta; 2012 Dec; 414():171-8. PubMed ID: 22926063
[TBL] [Abstract][Full Text] [Related]
12. BACE1 Physiological Functions May Limit Its Use as Therapeutic Target for Alzheimer's Disease.
Barão S; Moechars D; Lichtenthaler SF; De Strooper B
Trends Neurosci; 2016 Mar; 39(3):158-169. PubMed ID: 26833257
[TBL] [Abstract][Full Text] [Related]
13. Conformational transition in the substrate binding domain of β-secretase exploited by NMA and its implication in inhibitor recognition: BACE1-myricetin a case study.
Chakraborty S; Kumar S; Basu S
Neurochem Int; 2011 Jul; 58(8):914-23. PubMed ID: 21354237
[TBL] [Abstract][Full Text] [Related]
14. BACE1 Inhibition by Genistein: Biological Evaluation, Kinetic Analysis, and Molecular Docking Simulation.
Youn K; Park JH; Lee S; Lee S; Lee J; Yun EY; Jeong WS; Jun M
J Med Food; 2018 Apr; 21(4):416-420. PubMed ID: 29444415
[TBL] [Abstract][Full Text] [Related]
15. Flavanone glycosides inhibit β-site amyloid precursor protein cleaving enzyme 1 and cholinesterase and reduce Aβ aggregation in the amyloidogenic pathway.
Ali MY; Jannat S; Edraki N; Das S; Chang WK; Kim HC; Park SK; Chang MS
Chem Biol Interact; 2019 Aug; 309():108707. PubMed ID: 31194956
[TBL] [Abstract][Full Text] [Related]
16. Computational modelling of potent β-secretase (BACE1) inhibitors towards Alzheimer's disease treatment.
Ugbaja SC; Sanusi ZK; Appiah-Kubi P; Lawal MM; Kumalo HM
Biophys Chem; 2021 Mar; 270():106536. PubMed ID: 33387910
[TBL] [Abstract][Full Text] [Related]
17. The selective BACE1 inhibitor VIa reduces amyloid-β production in cell and mouse models of Alzheimer's disease.
Cheng X; Zhou Y; Gu W; Wu J; Nie A; Cheng J; Zhou J; Zhou W; Zhang Y
J Alzheimers Dis; 2013; 37(4):823-34. PubMed ID: 23948917
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of BACE1 Activity by a DNA Aptamer in an Alzheimer's Disease Cell Model.
Liang H; Shi Y; Kou Z; Peng Y; Chen W; Li X; Li S; Wang Y; Wang F; Zhang X
PLoS One; 2015; 10(10):e0140733. PubMed ID: 26473367
[TBL] [Abstract][Full Text] [Related]
19. Beta-secretase (BACE) as a drug target for Alzheimer's disease.
Vassar R
Adv Drug Deliv Rev; 2002 Dec; 54(12):1589-602. PubMed ID: 12453676
[TBL] [Abstract][Full Text] [Related]
20. Biological Evaluation and Docking Analysis of Potent BACE1 Inhibitors from
Youn K; Jun M
Nutrients; 2019 Mar; 11(3):. PubMed ID: 30893825
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
